Cost-Effectiveness of a Continuous Glucose Monitoring Mobile App for Patients With Type 2 Diabetes Mellitus: Analysis Simulation

BackgroundApps for real-time continuous glucose monitoring (CGM) on smartphones and other devices linked to CGM systems have recently been developed, and such CGM apps are also coming into use in Japan. In comparison with conventional retrospective CGM, the use of CGM apps im...

Full description

Bibliographic Details
Main Authors: Tsuji, Shintaro, Ishikawa, Tomoki, Morii, Yasuhiro, Zhang, Hongjian, Suzuki, Teppei, Tanikawa, Takumi, Nakaya, Jun, Ogasawara, Katsuhiko
Format: Article
Language:English
Published: JMIR Publications 2020-09-01
Series:Journal of Medical Internet Research
Online Access:https://www.jmir.org/2020/9/e16053
id doaj-d41a94854f7d40e7b1dfd0a54d94fabc
record_format Article
spelling doaj-d41a94854f7d40e7b1dfd0a54d94fabc2021-04-02T18:41:01ZengJMIR PublicationsJournal of Medical Internet Research1438-88712020-09-01229e1605310.2196/16053Cost-Effectiveness of a Continuous Glucose Monitoring Mobile App for Patients With Type 2 Diabetes Mellitus: Analysis SimulationTsuji, ShintaroIshikawa, TomokiMorii, YasuhiroZhang, HongjianSuzuki, TeppeiTanikawa, TakumiNakaya, JunOgasawara, Katsuhiko BackgroundApps for real-time continuous glucose monitoring (CGM) on smartphones and other devices linked to CGM systems have recently been developed, and such CGM apps are also coming into use in Japan. In comparison with conventional retrospective CGM, the use of CGM apps improves patients’ own blood glucose control, which is expected to help slow the progression of type 2 diabetes mellitus (DM) and prevent complications, but the effect of their introduction on medical costs remains unknown. ObjectiveOur objective in this study was to perform an economic appraisal of CGM apps from the viewpoint of assessing public medical costs associated with type 2 DM, using the probability of developing type 2 DM–associated complications, and data on medical costs and utility value to carry out a medical cost simulation using a Markov model in order to ascertain the cost-effectiveness of the apps. MethodsWe developed a Markov model with the transition states of insulin therapy, nephrosis, dialysis, and cardiovascular disease, all of which have a major effect on medical costs, to identify changes in medical costs and utility values resulting from the introduction of a CGM app and calculated the incremental cost-effectiveness ratio (ICER). ResultsThe ICER for CGM app use was US $33,039/quality-adjusted life year (QALY). ConclusionsSensitivity analyses showed that, with the exception of conditions where the transition probability of insulin therapy, utility value, or increased medical costs increases, the ICER for the introduction of CGM apps was below the threshold of US $43,478/QALY used by the Central Social Insurance Medical Council. Our results provide basic data on the cost-effectiveness of introducing CGM apps, which are currently starting to come into use.https://www.jmir.org/2020/9/e16053
collection DOAJ
language English
format Article
sources DOAJ
author Tsuji, Shintaro
Ishikawa, Tomoki
Morii, Yasuhiro
Zhang, Hongjian
Suzuki, Teppei
Tanikawa, Takumi
Nakaya, Jun
Ogasawara, Katsuhiko
spellingShingle Tsuji, Shintaro
Ishikawa, Tomoki
Morii, Yasuhiro
Zhang, Hongjian
Suzuki, Teppei
Tanikawa, Takumi
Nakaya, Jun
Ogasawara, Katsuhiko
Cost-Effectiveness of a Continuous Glucose Monitoring Mobile App for Patients With Type 2 Diabetes Mellitus: Analysis Simulation
Journal of Medical Internet Research
author_facet Tsuji, Shintaro
Ishikawa, Tomoki
Morii, Yasuhiro
Zhang, Hongjian
Suzuki, Teppei
Tanikawa, Takumi
Nakaya, Jun
Ogasawara, Katsuhiko
author_sort Tsuji, Shintaro
title Cost-Effectiveness of a Continuous Glucose Monitoring Mobile App for Patients With Type 2 Diabetes Mellitus: Analysis Simulation
title_short Cost-Effectiveness of a Continuous Glucose Monitoring Mobile App for Patients With Type 2 Diabetes Mellitus: Analysis Simulation
title_full Cost-Effectiveness of a Continuous Glucose Monitoring Mobile App for Patients With Type 2 Diabetes Mellitus: Analysis Simulation
title_fullStr Cost-Effectiveness of a Continuous Glucose Monitoring Mobile App for Patients With Type 2 Diabetes Mellitus: Analysis Simulation
title_full_unstemmed Cost-Effectiveness of a Continuous Glucose Monitoring Mobile App for Patients With Type 2 Diabetes Mellitus: Analysis Simulation
title_sort cost-effectiveness of a continuous glucose monitoring mobile app for patients with type 2 diabetes mellitus: analysis simulation
publisher JMIR Publications
series Journal of Medical Internet Research
issn 1438-8871
publishDate 2020-09-01
description BackgroundApps for real-time continuous glucose monitoring (CGM) on smartphones and other devices linked to CGM systems have recently been developed, and such CGM apps are also coming into use in Japan. In comparison with conventional retrospective CGM, the use of CGM apps improves patients’ own blood glucose control, which is expected to help slow the progression of type 2 diabetes mellitus (DM) and prevent complications, but the effect of their introduction on medical costs remains unknown. ObjectiveOur objective in this study was to perform an economic appraisal of CGM apps from the viewpoint of assessing public medical costs associated with type 2 DM, using the probability of developing type 2 DM–associated complications, and data on medical costs and utility value to carry out a medical cost simulation using a Markov model in order to ascertain the cost-effectiveness of the apps. MethodsWe developed a Markov model with the transition states of insulin therapy, nephrosis, dialysis, and cardiovascular disease, all of which have a major effect on medical costs, to identify changes in medical costs and utility values resulting from the introduction of a CGM app and calculated the incremental cost-effectiveness ratio (ICER). ResultsThe ICER for CGM app use was US $33,039/quality-adjusted life year (QALY). ConclusionsSensitivity analyses showed that, with the exception of conditions where the transition probability of insulin therapy, utility value, or increased medical costs increases, the ICER for the introduction of CGM apps was below the threshold of US $43,478/QALY used by the Central Social Insurance Medical Council. Our results provide basic data on the cost-effectiveness of introducing CGM apps, which are currently starting to come into use.
url https://www.jmir.org/2020/9/e16053
work_keys_str_mv AT tsujishintaro costeffectivenessofacontinuousglucosemonitoringmobileappforpatientswithtype2diabetesmellitusanalysissimulation
AT ishikawatomoki costeffectivenessofacontinuousglucosemonitoringmobileappforpatientswithtype2diabetesmellitusanalysissimulation
AT moriiyasuhiro costeffectivenessofacontinuousglucosemonitoringmobileappforpatientswithtype2diabetesmellitusanalysissimulation
AT zhanghongjian costeffectivenessofacontinuousglucosemonitoringmobileappforpatientswithtype2diabetesmellitusanalysissimulation
AT suzukiteppei costeffectivenessofacontinuousglucosemonitoringmobileappforpatientswithtype2diabetesmellitusanalysissimulation
AT tanikawatakumi costeffectivenessofacontinuousglucosemonitoringmobileappforpatientswithtype2diabetesmellitusanalysissimulation
AT nakayajun costeffectivenessofacontinuousglucosemonitoringmobileappforpatientswithtype2diabetesmellitusanalysissimulation
AT ogasawarakatsuhiko costeffectivenessofacontinuousglucosemonitoringmobileappforpatientswithtype2diabetesmellitusanalysissimulation
_version_ 1721551204287250432